Impax launches generic Avodart

HAYWARD, Calif. — Impax Laboratories announced Wednesday that it would be launching its generic of Avodart (dutasteride) capsules after it received Food and Drug Administration approval on Nov. 20. The capsules, which treat benign prostatic hyperplasia (prostate gland enlargement), will be available in 0.5-mg dosage strength. 

 

The drug, according to IMS Health data for the 12 months eneding Sept. 2015, had combined brand and generic sales of $457 million. This is the company’s 13th generic launched this year.